Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months
Health officials have previously raised the possibility that the public may need booster COVID-19 shots.
Pfizer's chief executive Dr Albert Bourla told the BBC that he is of the view that annual vaccinations would be needed to maintain a "very high level of protection" against the deadly disease that has claimed over five million lives across the world.
Pfizer and BioNTech SE on Monday said trial results of COVID-19 vaccine showed that it is safe and produced robust neutralising antibody response in children aged five to 11 years, and they plan to seek regulatory approvals as soon as possible.
The Quad partnership is on track to produce at least a billion vaccine doses in India by 2022, US President Joe Biden said on Wednesday, asserting that nothing is more urgent than working together to defeat COVID-19 so the world is much better prepared for future pandemics.
Earlier in April, Pfizer said that it had offered a not-for-profit price for its vaccine for the government immunisation programme in India and it remains committed to continuing engagement with the government to make the vaccine available in India.
United States Pharma giant Pfizer is in the final stages of an agreement with India to supply anti-COVID-19 vaccines, Chief Executive Officer Dr Albert Bourla said on Tuesday, observing that the domestically manufactured vaccines would be the backbone of vaccinating the Indian people.
The news comes as the United States approaches 300,000 deaths from COVID-19.
According to the organisers, based on the feedback from the NOCs and NPCs, it is expected that a significant proportion of Games participants will have been vaccinated before arriving in Japan. The new MoU adds to these efforts.
The vaccine arrives at a critical moment for the US. Hospitalisations due to COVID-19 hit record highs for the seventh day in a row on Saturday.
After discussion with the Food and Drug Administration (FDA), the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases, the statement said.
More than 200 million Pfizer doses have been administered in the US, and hundreds of millions more worldwide, since December.
Providing data, it said UK's Public Health England has reported high vaccine effectiveness (87.9 per cent) against the B.1.617.2 variant, most reported in India, in an observational study (concluded on May 22, 2021).
Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances